NovoCure Limited (NVCR) Stock
Key stats
- Market cap
- $1.40B
- Price / Earnings ratio
- -11.3x
- EPS (TTM)
- -$1.06
- Volume
- Loading
- 52-week high
- $21.45
- 52-week low
- $9.82
Source: third-party data provider, as of November 13, 2026
Compare with NVCR
Recent news
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
NVCR
NovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure: 3 Key Takeaways for Long-Term Investors
NVCR
NovoCure Q3 Earnings Call Highlights
NovoCure Q3 Earnings Call Highlights
NVCR
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
NVCRNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 33.79
- MACD 12/26/9
- -0.76
- EMA 9 of MACD
- -0.60
- MACD histogram
- -0.17
- SMA 50
- $15.07
- Price below SMA 50
- EMA 50
- $14.71
- Price below EMA 50
- SMA 200
- $14.80
- Price below SMA 200
- EMA 200
- $14.51
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.33 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
Don't Overlook NovoCure (NVCR) International Revenue Trends While Assessing the Stock
NVCRNovoCure: 3 Key Takeaways for Long-Term Investors
NovoCure: 3 Key Takeaways for Long-Term Investors
NVCRNovoCure Q3 Earnings Call Highlights
NovoCure Q3 Earnings Call Highlights
NVCRNovocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
Novocure CEO Says RVMD’s Daraxonrasib Slowed Optune Pax Adoption – Wedbush Sees Disruption Rather Than Direct Competition
NVCR
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NovoCure (NVCR) Reports Q3 Loss, Tops Revenue Estimates
NVCR
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
Novocure Reports Third Quarter 2026 Financial Results and Raises 2026 Guidance
NVCR
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
Novocure to Evaluate Tumor Treating Fields Therapy with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement
NVCR
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
NVCR
Novocure to Report Third Quarter 2026 Financial Results
Novocure to Report Third Quarter 2026 Financial Results
NVCR
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NovoCure Eyes Glioblastoma Growth, Cancer Launches and EBITDA Break-Even
NVCRNews tone: automated (AI) classification of the article's content, not a price prediction.
About NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Frank Leonard | CEO & Director | — |
| Mr. William F. Doyle | Executive Chairman | 1962 |
| Mr. Christoph Brackmann | Chief Financial Officer | 1974 |
| Mr. Mukund Paravasthu | Chief Operating Officer | 1970 |
| Mr. Michael Puri | Chief Human Resources Officer | 1969 |
| Dr. Uri Weinberg M.D., Ph.D. | Chief Innovation Officer & Chief Medical Officer | 1978 |
| Mr. Adam Daney | Head of Investor Relations | — |
| Mr. Barak Ben-Arye | General Counsel | 1977 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 33.79
- MACD 12/26/9
- -0.76
- EMA 9 of MACD
- -0.60
- MACD histogram
- -0.17
- SMA 50
- $15.07
- Price below SMA 50
- EMA 50
- $14.71
- Price below EMA 50
- SMA 200
- $14.80
- Price below SMA 200
- EMA 200
- $14.51
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $15.00
- Average
- $21.25
- High
- $31.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.7 | -17.6 | ||||||||||
| 2022 | -14.3 | +14.0 | +2.8 | -12.6 | -1.2 | -13.2 | -7.2 | +19.0 | -3.5 | -9.3 | +5.0 | -10.0 |
| 2023 | +34.2 | -15.5 | -21.2 | +9.5 | +7.3 | -44.6 | -22.9 | -32.4 | -27.5 | -14.7 | -6.3 | +19.4 |
| 2024 | -3.3 | +4.4 | -3.8 | -21.0 | +72.8 | -28.3 | +31.2 | -9.2 | -6.7 | +1.9 | +23.9 | -0.2 |
| 2025 | -18.2 | -19.7 | -3.2 | +3.5 | +6.5 | +4.5 | -35.3 | +8.9 | +6.0 | -8.4 | +4.7 | +10.7 |
| 2026 | -5.5 | +12.1 | -19.4 | +40.3 | +2.5 | -8.5 | -6.0 | +15.2 | -8.2 | -17.4 | -9.2 |
